Shares of Akero Therapeutics AKRO skyrocketed 105.7% in a week after the company announced initial positive top line 96-week ...

When cystic fibrosis hits your lungs hard, hit back. Everything you need to know about getting your lungs back into shape is ...

Akero Therapeutics reports a 39% improvement in cirrhosis patients using EFX. See why AKRO stock is soaring with the ...

Akero Therapeutics announced statistically significant results from a Phase 2b trial of efruxifermin this week, a fibroblast ...

Akero Therapeutics nearly doubled Monday — and pulled 89bio shares higher — after the company's treatment for MASH ...

After missing the primary endpoint in the Phase IIb SYMMETRY trial, Akero Therapeutics’ lead molecule, efruxifermin, showed ...

Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 ...

Akero Therapeutics, Inc. (NASDAQ:AKRO) released preliminary topline week 96 results from SYMMETRY Phase 2b study evaluating ...

Akero reported Monday strong results showing its drug efruxifermin reversed liver scarring in patients with cirrhosis caused ...

Most ICBs in England do not have effective referral pathways for diagnosing and managing liver disease, an analysis has shown ...

Right now, patients with obesity and cirrhosis have few treatments for their progressive liver disease, but a new study ...

Our livers contain many different types of immune cells. New research by the team of Prof. Charlotte Scott (VIB-UGent Center ...